Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions are flooding the market. From cardiology and imaging to oncology and primary care, clinicians are being asked to evaluate algorithms that promise earlier detection, better accuracy, and more efficient care. Many of these tools are technically impressive. Some are FDA-cleared. A few even come with early clinical data. Yet only a relatively small number have become part of routine clinical practice.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Related Articles
How Mayo Clinic is using AI to spot hidden heart conditions
Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step…May 31, 2021
Trial demonstrates early AI-guided detection of heart disease in routine practice
Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the…May 15, 2021
Supporting Predictive Analytics to Improve Clinical Decision Making and Patient Outcomes
As we strive to improve clinical decison making and patient outcomes – predictive analytics are a wonderful tool to help us in that goal. But you can’t just decide to throw predictive analytics into…November 26, 2025
Anumana Names Dr. Simos Kedikoglou President & COO
AI Tech 365: Anumana, a leading AI-driven health technology company, announced the appointment of Dr. Simos Kedikoglou as President and Chief Operating Officer (COO), effective immediately.January 10, 2025


